Vor Bio announces additional Phase 1/2a data: trem-cel protects against Mylotarg hematotoxicity in AML patients

Vor Biopharma Inc.

First AML patient maintained neutrophil and platelet counts ~5 months post trem-cel transplant through three Mylotarg doses at 0.5 mg/m².
No Mylotarg-related hematotoxicity observed; only low-grade nausea/vomiting reported as possibly related.
Second patient engrafted normally with neutrophil recovery Day 11, platelet recovery Day 17; no unexpected AEs in both patients.
CD33-negative donor hematopoiesis enriched across cell types after Mylotarg, suggesting potential for combo therapy.
Company on track to file IND in H1 2023 for VCAR33 ALLO allogeneic CAR-T to combine with trem-cel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.